Athenex acquires Houston biotech co. Kuur Therapeutics for $185M
Kuur Therapeutics develops cellular immunotherapies targeting cancer using a platform created by a Baylor College of Medicine and Texas Children’s Hospital researcher.
Read More
Building "Bridges" Across the Bayou City!
Kuur Therapeutics develops cellular immunotherapies targeting cancer using a platform created by a Baylor College of Medicine and Texas Children’s Hospital researcher.
Read MoreIterion Therapeutics is investigating its lead clinical candidate, Tegavivint, in a Phase 1/2a clinical trial in patients with desmoid turmors.
Read More